Linklaters has advised Takeda on the completed sale of TachoSil to Corza Health, Inc for €350 million. It follows the firm previously advising Takeda on its £46 billion takeover of Shire in 2018.
TachoSil is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Under the terms of the transaction, Corza has acquired the assets and licenses that support the development and commercialization of TachoSil, while Takeda maintains ownership of the manufacturing facility in Linz, Austria.
As part of Takeda’s acquisition of Shire in 2018, Takeda committed to divest up to $10 billion of non-core assets. TachoSil is the latest divestment from Takeda after exceeding its $10 billion non-core asset divestiture target, announcing 11 deals since January 2019 to date for a total aggregate value of up to approximately $11.6 billion.
Aisling Zarraga, partner at Linklaters who advised Takeda on the deal, commented:
“We are pleased to have once again supported Takeda on achieving its long-term growth strategy, this time with a key divestment that secures the future of the TachoSil business.”
The Linklaters team was led by partners Aisling Zarraga (Mainstream Corporate, London) and James Inglis (Mainstream Corporate, London) with managing associate Nicole Meyer (Mainstream Corporate, London) and associate Meila Burgess (Mainstream Corporate, London). Partner Marly Didizian (Commercial, London) and managing associate Rich Jones (Commercial, London) advised on manufacturing and supply aspects, whilst partners Jonas Koponen (Antitrust & Foreign Investment, Brussels) and Thomas McGrath (Antitrust & Foreign Investment, New York) advised on antitrust aspects.
